Drug Profile

GT 719

Alternative Names: GT-719

Latest Information Update: 13 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GRIT Biotechnology
Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Phase I/II Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Phase I Immunological disorders
Phase 0 Kidney disorders

31 Jan 2026 Phase-0 for Kidney disorders (Treatment-experienced) in China (Parenteral) (NCT07389499)
20 Aug 2025 Grit Biotechnology plans a phase 0 trial for Autoimmune disorders in China (Parenteral; Injection) in August 2025 (NCT07132112)
14 Aug 2025 Grit Biotechnology plans a phase 0 trial for Autoimmune Diseases (In adults), in China in August 2025 (Parenteral, Injection) (NCT07122076)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com